Gleevec/Glivec

India has big plans for healthcare and pharma

A number of court cases are proceeding and earlier this year the Indian Supreme Court denied Novartis patent protection for its cancer drug Glivec.

Bayer wins GIST approval for Stivarga in EU

Cancer drug can be used after Pfizer’s Sutent and Novartis’ Glivec.  . ... Patients must have progressed on - or must be intolerant to - prior treatment with Novartis' Glivec (imatinib) and Pfizer's Sutent (sunitinib) and the European Commission

Novartis' vaccine sales decline ahead of GSK transfer

for cancers affecting the bone and the start of generic competition to leukaemia therapy Glivec (imatinib). ... The first generic for Glivec is due in the US market in February 2016, although Novartis is hopeful that the oncology portfolio due to be

Novartis pulls EMA application for expanded Tasigna use

molecular response' when treated with the company's Glivec/Gleevec (imatinib).

Niche-busting cancer immunotherapies

Novartis's Glivec represents the first real advance in getting 'under the hood' of cancer at the molecular level. ... By targeting a protein made by a mutated gene, Glivec has allowed chronic myeloid leukaemia (CML) patients to live nearly normal lives

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]